Angsana Molecular and Diagnostics

Singapore, Singapore Founded: 2014 • Age: 12 yrs Acquired By Parkway Pantai
Genomic assays for oncology, immunology, and pharmacogenomics are provided.
Request Access

About Angsana Molecular and Diagnostics

Angsana Molecular and Diagnostics is a company based in Singapore (Singapore) founded in 2014 by Chris Tan was acquired by Parkway Pantai in July 2017.. Angsana Molecular and Diagnostics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.

  • Headquarter Singapore, Singapore
  • Founders Chris Tan
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Parkway Pantai Limited
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    Parkway Pantai

    (Jul 31, 2017)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Angsana Molecular and Diagnostics

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Angsana Molecular and Diagnostics

Angsana Molecular and Diagnostics has secured backing from 1 investor. Prominent investors backing the company include Parkway Pantai. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
A chain of multispecialty hospitals is operated in Singapore.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Angsana Molecular and Diagnostics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Angsana Molecular and Diagnostics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Angsana Molecular And Diagnostics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Angsana Molecular and Diagnostics

Angsana Molecular and Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
domain founded_year HQ Location
MicroRNA-based therapeutics are developed for treating multiple diseases.
domain founded_year HQ Location
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
domain founded_year HQ Location
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
domain founded_year HQ Location
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
domain founded_year HQ Location
Therapeutics for aging diseases are developed by targeting senescent cells.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Angsana Molecular And Diagnostics

Frequently Asked Questions about Angsana Molecular and Diagnostics

When was Angsana Molecular and Diagnostics founded?

Angsana Molecular and Diagnostics was founded in 2014.

Where is Angsana Molecular and Diagnostics located?

Angsana Molecular and Diagnostics is headquartered in Singapore, Singapore.

Who is the current CEO of Angsana Molecular and Diagnostics?

Chris Tan is the current CEO of Angsana Molecular and Diagnostics. They have also founded this company.

What does Angsana Molecular and Diagnostics do?

Angsana Molecular and Diagnostics was established in 2014 in Singapore. Genomic assays are offered in the diagnostics sector, focusing on oncology, immunology, and pharmacogenomics. Molecular and genetic profiling are integrated to address innate immunity and support individualized medicine prescriptions. Additional tests are provided for oncology applications, prenatal and postnatal fetal and maternal assessments, allergies, and pharmacogenetics, with operations centered in Singapore.

Who are the top competitors of Angsana Molecular and Diagnostics?

Angsana Molecular and Diagnostics's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.

Who are Angsana Molecular and Diagnostics's investors?

Angsana Molecular and Diagnostics has 1 investor. Key investors include Parkway Pantai.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available